About Viva Biotech - About Us

Home / About Us / About Viva Biotech

Established in 2008, Viva Biotech Holdings (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. Leveraging our leading edge in AI-driven structure-based drug discovery (SBDD), the Company provides CRO services covering the drug discovery stage to global partners. Through the synergistic development of its biology and chemistry capabilities, the Company has established an integrated R&D platform spanning multiple drug modalities, including small molecules, large molecules/antibodies, peptides, PROTACs/molecular glues, and XDCs. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC/CDMO solution from preclinical to commercial manufacturing. Additionally, we embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2026, Viva Biotech has cumulatively provided drug discovery and manufacturing services to 2,904 biotech and pharmaceutical clients worldwide, and has invested in and incubated 93 portfolio companies. In the future, the Company will continue to provide high-quality, diversified services to clients worldwide, benefiting patients around the world.

2,904

Biotech and pharmaceutical clients worldwide
2,213

Employees worldwide
67

Domestic and foreign patents
93

Invested and incubated companies

cro

Drug R&D Services

With its leading position in Structure-Based Drug Discovery (SBDD), Viva provides state-of-the-art drug research and development services to global biotechnology and pharmaceutical customers for their preclinical, innovative drug discovery programs. We cover the all-around needs of our clients for their early drug research and development, including protein expression, purification and structure determination, hits screening, therapeutic antibody discovery, antibody expression and production, Bioassay, computer-aided drug design, medicinal chemistry and custom synthesis, ADME, and PK studies.

Learn more

cdmo

R&D and Production Services

As the subsidiary of Viva Biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.

Learn more

Langhua Pharmaceutical

Langhua Pharmaceutical, a subsidiary of Viva Biotech Holdings, is a comprehensive pharmaceutical company engaged in drug research, development and production. Langhua offers our worldwide partners a One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.

More

SYNthesis med chem

SYNthesis, as a subsidiary of Viva Biotech Holdings, has a highly synergistic new drug development services and project management business that builds on the strengths of Viva's world leading one-stop platform from early-stage SBDD to commercial drug delivery. SYNthesis med chem is a provider of small molecule drug discovery services. Our focus is on the provision of world class medicinal and synthetic chemistry. We fit seamlessly into a client’s company to add capacity and insight to their drug discovery programs. We work with your scientists to accelerate programs from hit-to-lead through to lead optimisation and beyond. With a team of experienced biotech professionals we can contribute to an internal program or independently run a discovery effort. We understand the need for flexibility and cost effectiveness in drug discovery and aim to provide a scalable service to our clients.

More